[
  {
    "level": "VOI",
    "name": "B.1.525",
    "spike_subs": [
      "A67V",
      "69del",
      "70del",
      "144del",
      "E484K",
      "D614G",
      "Q677H",
      "F888L"
    ],
    "nextstrain": "20A/S:484K",
    "who_label": "Eta",
    "first_detection": "United Kingdom/Nigeria - December 2020",
    "ref_isolate": "",
    "attributes": [
      "Potential reduction in neutralization by some EUA monoclonal antibody treatments",
      "Potential reduction in neutralization by convalescent and postvaccination sera"
    ]
  },
  {
    "level": "VOI",
    "name": "B.1.526",
    "spike_subs": [
      "(L5F*)",
      "T95I",
      "D253G",
      "(S477N*)",
      "(E484K*)",
      "D614G",
      "(A701V*)"
    ],
    "nextstrain": "20C/S:484K",
    "who_label": "Iota",
    "first_detection": "United States (New York) - November 2020",
    "ref_isolate": "NR-55359",
    "attributes": [
      "Reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, the clinical implications of this are not known. Alternative monoclonal antibody treatments are available.",
      "Reduced neutralization by convalescent and postvaccination sera"
    ]
  },
  {
    "level": "VOI",
    "name": "B.1.526.1",
    "spike_subs": [
      "D80G",
      "144del",
      "F157S",
      "L452R",
      "D614G",
      "(T791I*)",
      "(T859N*)",
      "D950H"
    ],
    "nextstrain": "20C",
    "who_label": "",
    "first_detection": "United States (New York) - October 2020",
    "ref_isolate": "",
    "attributes": [
      "Potential reduction in neutralization by some EUA monoclonal antibody treatments",
      "Potential reduction in neutralization by convalescent and postvaccination sera"
    ]
  },
  {
    "level": "VOI",
    "name": "B.1.617",
    "spike_subs": ["L452R", "E484Q", "D614G"],
    "nextstrain": "20A",
    "who_label": "",
    "first_detection": "India - February 2021",
    "ref_isolate": "",
    "attributes": [
      "Potential reduction in neutralization by some EUA monoclonal antibody treatments",
      "Reduced neutralization by postvaccination sera"
    ]
  },
  {
    "level": "VOI",
    "name": "B.1.617.1",
    "spike_subs": [
      "(T95I)",
      "G142D",
      "E154K",
      "L452R",
      "E484Q",
      "D614G",
      "P681R",
      "Q1071H"
    ],
    "nextstrain": "20A/S:154K",
    "who_label": "Kappa",
    "first_detection": "India - December 2020",
    "ref_isolate": "",
    "attributes": [
      "Potential reduction in neutralization by some EUA monoclonal antibody treatments",
      "Potential reduction in neutralization by postvaccination sera"
    ]
  },
  {
    "level": "VOI",
    "name": "B.1.617.3",
    "spike_subs": [
      "T19R",
      "G142D",
      "L452R",
      "E484Q",
      "D614G",
      "P681R",
      "D950N"
    ],
    "nextstrain": "20A",
    "who_label": "",
    "first_detection": "India - October 2020",
    "ref_isolate": "",
    "attributes": [
      "Potential reduction in neutralization by some EUA monoclonal antibody treatments",
      "Potential reduction in neutralization by postvaccination sera"
    ]
  },
  {
    "level": "VOI",
    "name": "P.2",
    "spike_subs": ["E484K", "(F565L*)", "D614G", "V1176F"],
    "nextstrain": "20J",
    "who_label": "Zeta",
    "first_detection": "Brazil - April 2020",
    "ref_isolate": "",
    "attributes": [
      "Potential reduction in neutralization by some EUA monoclonal antibody treatments",
      "Reduced neutralization by postvaccination sera"
    ]
  },
  {
    "level": "VOC",
    "name": "B.1.1.7",
    "spike_subs": [
      "69del",
      "70del",
      "144del",
      "(E484K*)",
      "(S494P*)",
      "N501Y",
      "A570D",
      "D614G",
      "P681H",
      "T716I",
      "S982A",
      "D1118H (K1191N*)"
    ],
    "nextstrain": "20I/501Y.V1",
    "who_label": "Alpha",
    "first_detection": "United Kingdom",
    "ref_isolate": "NR-54000",
    "attributes": [
      "~% increased transmission",
      "Potential increased severity based on hospitalizations and case fatality rates",
      "No impact on susceptibility to EUA monoclonal antibody treatments",
      "Minimal impact on neutralization by convalescent and postvaccination sera"
    ]
  },
  {
    "level": "VOC",
    "name": "B.1.351",
    "spike_subs": [
      "D80A",
      "D215G",
      "241del",
      "242del",
      "243del",
      "K417N",
      "E484K",
      "N501Y",
      "D614G",
      "A701V"
    ],
    "nextstrain": "20H/501.V2",
    "who_label": "Beta",
    "first_detection": "South Africa",
    "ref_isolate": "NR-55282",
    "attributes": [
      "~% increased transmission",
      "Significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment, but other EUA monoclonal antibody treatments are available",
      "Reduced neutralization by convalescent and postvaccination sera"
    ]
  },
  {
    "level": "VOC",
    "name": "B.1.427",
    "spike_subs": ["L452R", "D614G"],
    "nextstrain": "20C/S:452R",
    "who_label": "Epsilon",
    "first_detection": "United States-(California)",
    "ref_isolate": "",
    "attributes": [
      "~% increased transmission",
      "Modest decrease in susceptibility to the combination of bamlanivimab and etesevimab; however, the clinical implications of this decrease are not known. Alternative monoclonal antibody treatments are available.",
      "Reduced neutralization by convalescent and postvaccination sera"
    ]
  },
  {
    "level": "VOC",
    "name": "B.1.429",
    "spike_subs": ["S13I", "W152C", "L452R", "D614G"],
    "nextstrain": "20C/S:452R",
    "who_label": "Epsilon",
    "first_detection": "United States-(California)",
    "ref_isolate": "",
    "attributes": [
      "~% increased transmission",
      "Reduced susceptibility to the combination of bamlanivimab and etesevimab; however, the clinical implications of this decrease are not known. Alternative monoclonal antibody treatments are available.",
      "Reduced neutralization by convalescent and postvaccination sera"
    ]
  },
  {
    "level": "VOC",
    "name": "B.1.617.2",
    "spike_subs": [
      "Spike:\u00a0T19R",
      "(G142D)",
      "156del",
      "157del",
      "R158G",
      "L452R",
      "T478K",
      "D614G",
      "P681R",
      "D950N"
    ],
    "nextstrain": "20A/S:478K",
    "who_label": "Delta",
    "first_detection": "India",
    "ref_isolate": "",
    "attributes": [
      "Increased transmissibility",
      "Potential reduction in neutralization by some EUA monoclonal antibody treatments",
      "Potential reduction in neutralization by postvaccination sera"
    ]
  },
  {
    "level": "VOC",
    "name": "P.1",
    "spike_subs": [
      "L18F",
      "T20N",
      "P26S",
      "D138Y",
      "R190S",
      "K417T",
      "E484K",
      "N501Y",
      "D614G",
      "H655Y",
      "T1027I"
    ],
    "nextstrain": "20J/501Y.V3",
    "who_label": "Gamma",
    "first_detection": "Japan/Brazil",
    "ref_isolate": "NR-54982",
    "attributes": [
      "Significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment, but other EUA monoclonal antibody treatments are available",
      "Reduced neutralization by convalescent and postvaccination sera"
    ]
  }
]
